CDK9/HDAC1/HDAC3-IN-1

CDK9/HDAC1/HDAC3-IN-1 is a dual inhibitor targeting CDK9 and HDAC enzymes. It potently suppresses the activity of CDK9, HDAC1, and HDAC3, with IC50 values of 0.17 μM, 1.73 μM, and 1.11 μM, respectively. The compound inhibits cancer cell growth by inducing apoptosis and causing cell cycle arrest at the G2/M phase. In a mouse model using TNBC MDA-MB-231 xenografts, it effectively hinders tumor progression. This compound exhibits broad-spectrum anticancer effects, notably against breast cancer, cervical cancer, and liver cancer.